CN114062566B - Method for separating and identifying structure of related metabolites of even flower antipyretic drugs - Google Patents
Method for separating and identifying structure of related metabolites of even flower antipyretic drugs Download PDFInfo
- Publication number
- CN114062566B CN114062566B CN202010742940.3A CN202010742940A CN114062566B CN 114062566 B CN114062566 B CN 114062566B CN 202010742940 A CN202010742940 A CN 202010742940A CN 114062566 B CN114062566 B CN 114062566B
- Authority
- CN
- China
- Prior art keywords
- body fluid
- column
- resolution
- antipyretic
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000002221 antipyretic Substances 0.000 title claims abstract description 30
- 239000002207 metabolite Substances 0.000 title claims abstract description 21
- 210000001124 body fluid Anatomy 0.000 claims abstract description 32
- 239000010839 body fluid Substances 0.000 claims abstract description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 235000019253 formic acid Nutrition 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000002775 capsule Substances 0.000 claims description 26
- 210000002700 urine Anatomy 0.000 claims description 18
- 230000001754 anti-pyretic effect Effects 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 3
- 238000002309 gasification Methods 0.000 claims description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 238000012916 structural analysis Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 34
- 239000009929 lianhuaqingwen Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 description 30
- 238000001819 mass spectrum Methods 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 13
- 239000013558 reference substance Substances 0.000 description 13
- 239000007789 gas Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000004885 tandem mass spectrometry Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000005336 cracking Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CHBOSHOWERDCMH-UHFFFAOYSA-N 1-chloro-2,2-bis(4-chlorophenyl)ethane Chemical compound C=1C=C(Cl)C=CC=1C(CCl)C1=CC=C(Cl)C=C1 CHBOSHOWERDCMH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008530 yinqiaosan Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention provides a method for separating and identifying the structure of a related metabolite of a coptis chinensis antipyretic drug. The method comprises isolating the relevant metabolites in the body fluid of an individual administered a Lianhua qingwen drug using the following chromatographic conditions: chromatographic column: a C18 chromatographic column; mobile phase: a:0.1% formic acid aqueous solution, B: acetonitrile, volume ratio of A to B is (98-5): (2-95); flow rate: 0.3mL/min; column temperature: 35 ℃.
Description
Technical Field
The invention relates to the field of medicines, in particular to a method for separating and identifying structures of related metabolites of a coptis chinensis antipyretic drug.
Background
The Lianhua Qingshan capsule is a Chinese patent medicine produced by Kaolin pharmaceutical company Limited, and is carried by Chinese pharmacopoeia. The Lianhua qingwen formula absorbs the medication essence of the traditional Chinese medicine for treating epidemic diseases, takes the Ma Xingshi Gantn decoction specially used for treating epidemic diseases in Zhang Zhongjing (typhoid treatise) and Yinqiao san specially used for treating epidemic diseases in Qing Dynasty Wu Jutong (epidemic disease strip differentiation) as the main materials, and draws Ming Dynasty Wu (Chinese character) and can also be used for treating epidemic diseases in Sheng Ying Lun (epidemic disease treatise). The prescription is prepared by adopting a modern process according to the theory of traditional Chinese medicine (monarch, minister, assistant and guide) of China, wherein fructus forsythiae and honeysuckle are monarch drugs, and play roles in clearing heat, detoxicating and dispelling wind and heat. The three medicines of the roasted ephedra, the gypsum and the roasted bitter apricot seed are ministerial medicines, play roles in assisting monarch medicines to clear away lung fire and freeing lung and relieving asthma; the seven adjuvant drugs of the radix isatidis, the rhizoma dryopteris crassirhizomae, the cordate houttuynia, the menthol, the patchouli, the rheum officinale and the rhodiola rosea are combined together, so that the auxiliary drugs are used for clearing lung and detoxifying, dispersing lung and clearing heat, and resolving damp turbidity and regulating qi and regulating middle warmer. Glycyrrhrizae radix is used as a guiding drug to achieve the effects of clearing heat and detoxicating and harmonizing the drugs. The prescription is based on the traditional Chinese medicine theory prescription, is composed of 13 traditional Chinese medicines, has the effects of clearing away heat and toxic materials, ventilating the lung and dispelling heat, and is clinically used for treating the symptoms caused by the heat toxin stagnation lung syndrome of influenza. The composition of the coptis chinensis antipyretic capsule is complex, the substance basis and the action mechanism of the drink-making antipyretic capsule are explored, and the drink-making antipyretic capsule plays an important role in clinical application of the drink-making antipyretic capsule and development of novel antipyretic traditional Chinese medicines based on the Chinese medicine theory.
In the traditional Chinese medicine active ingredient research strategy, phytochemical separation analysis is often adopted as a guide, and the in-vitro activity is gradually changed into in-vivo activity research. The understanding of the traditional Chinese medicine and western medicine is unified on the basis of the substance for treating diseases, and the ingredients entering the body and the metabolites thereof are considered as the substance guarantee for exerting the drug effect. Therefore, the drug effect substance basis of the traditional Chinese medicine can be more intuitively observed on the whole through the research of substances in the body, and the whole appearance of the traditional Chinese medicine can be reflected. Different from the new chemical medicines, the clinical safety of the traditional Chinese medicine has been guaranteed by thousands of years of clinical practice experience. Traditional Chinese medicine is a subject developed from clinical practice, and the traditional Chinese medicine research starts from clinical research, and the human exposure research is directly carried out under the safe dosage, so that the actual action substance basis of the traditional Chinese medicine can be more intuitively reflected. The present study preliminarily analyzed the composition of Lianhua qingwen capsule in human body.
Disclosure of Invention
The invention aims at providing a method for separating a metabolite related to a coptis chinensis antipyretic drug;
the invention also aims to provide a structure identification method of the related metabolite of the even flower antipyretic drug. The method is not only beneficial to digging main medicinal components in the body of the Lianhua qingwen capsule, but also reveals the metabolic conversion process and excretion path of the Lianhua qingwen capsule in the body; and can provide reference basis for toxicology study and subsequent pharmacodynamic mechanism study of the Lianhua qingwen capsule; in addition, theoretical guidance can be provided for clinical treatment, so that the application of the medicine in clinic is promoted.
To achieve the above object, in one aspect, the present invention provides a method for separating a metabolite related to a continuous flower antipyretic drug, wherein the method comprises separating the metabolite related to a body fluid of an individual to whom the continuous flower antipyretic drug is administered by using the following chromatographic conditions:
chromatographic column: a C18 chromatographic column;
mobile phase: a:0.1% formic acid aqueous solution, B: acetonitrile, volume ratio of A to B is (98-5): (2-95);
flow rate: 0.2-0.3mL/min;
column temperature: 30-40 ℃.
According to some embodiments of the invention, wherein the flow rate in chromatographic conditions is 0.3mL/min.
According to some embodiments of the invention, wherein the column temperature in the chromatographic conditions is 35 ℃.
According to some embodiments of the invention, wherein the method further comprises eluting with a mobile phase gradient:
0-3min：2％-2％ B、3-4min：2％-5％ B、4-6min：5％-5％B、6-9min：5％-10％B、9-14min：10％-15％ B、14-18min：15％-20％ B、18-25min：20％-30％ B、25-28min：30％-95％、28-32min：95％-95％、32min：95％-5％ B、32-37min：5％-5％B。
wherein it can be understood that "0-3min:2% -2% B ", which means that the concentration of B is kept unchanged in the period of 0-3 min; the method is characterized in that the period of time is 3-4min:2% -5% B ", which means that the concentration of B is increased from 2% to 5% in a period of 3-4 min; other time periods and so on.
It is further understood that the end points of each of the above-mentioned time periods, particularly the end point of the previous time period and the start point of the subsequent time period, refer to the start point of the end point time, for example, "0-3min:2% -2% of B and 3-4min:2% -5% b "means that the concentration increases from 2% at the beginning of the 3 rd minute; but this point in time is allowed to have an error that is acceptable in the art (e.g., an error of 1 second before and after, or even 2 seconds).
Wherein the' 28-32min:95% -95%, 32min:95% -5% of B and 32-37min:5% -5% b "means that the concentration is changed from 95% to 5% at the beginning of 32min, and then the concentration is maintained from 5% to the end.
According to some embodiments of the invention, wherein the method further comprises eluting with a mobile phase gradient:
0-3min：2％-2％ B、3-4min：2％-5％ B、4-6min：5％-5％B、6-9min：5％-10％B、9-14min：10％-15％ B、14-18min：15％-20％ B、18-25min：20％-30％ B、25-28min：30％-95％、28-32min：95％-95％、32.01min：95％-5％ B、32.01-37min：5％-5％B。
according to some embodiments of the invention, wherein the method further comprises eluting with a mobile phase gradient:
0-3min:2% -2% of B and 3-4min:2% -5% of B and 4-6min:5% -5% of B and 6-9min:5% -10% of B and 9-14min:10% -15% of B and 14-18min:15% -20% of B and 18-25min:20% -30% of B and 25-28min:30% -95%, 28-32min:95% -95%, 32.01min:95% -5% of B and 32.01-37min:5% -5% of B; wherein the B concentration is increased at a constant rate during each period of time in which the B concentration is increased.
Wherein, in each period of time of increasing the concentration of B, the concentration of B is increased at a constant speed, which means, for example, "3-4min: the B concentration increases from 2% to 5% at a constant rate over a period of 3-4min of 2% -5% B ".
According to some embodiments of the invention, wherein the chromatography column is a ACQUITY UPLC CSH C18 chromatography column.
According to some embodiments of the invention, the chromatographic conditions further comprise a sample loading of 3 μl.
According to some embodiments of the invention, wherein the method comprises isolating the body fluid of the individual administered with the Lianhua qingfebrile drug using chromatography-mass spectrometry, wherein mass spectrometry conditions comprise: a positive and negative ion detection mode; full MS Full scan resolution: 70000; scanning quality range: 100-1200Da; full ms/ddMS2 collision energy: 30eV; full MS resolution: 35000; ddMS2 resolution: 17500.
according to some specific embodiments of the invention, the even flower antipyretic drug is even flower antipyretic capsule or even flower antipyretic granule.
According to some embodiments of the invention, wherein the subject is a mammalian subject.
According to some embodiments of the invention, wherein the individual is a human.
According to some embodiments of the invention, the body fluid is blood and/or urine.
According to some embodiments of the invention, the method comprises enriching and purifying the body fluid with column chromatography and then separating.
According to some embodiments of the invention, the method comprises enriching and purifying the body fluid with an extraction column and then separating the body fluid.
According to some of the inventionIn particular embodiments, wherein, when the body fluid is blood, the extraction column isAn HLB 3cc (60 mg) Extraction Cartridges (Batch No. 164A 39127A) column; when the body fluid is urine, the extraction column is an Oasis HLB SPE (60 mg/3 cc) column.
According to some embodiments of the invention, the method comprises subjecting the body fluid to column chromatography, eluting with methanol, drying, re-dissolving the obtained dried product with methanol, centrifuging, and collecting supernatant for separation.
According to some embodiments of the invention, the drying is drying with nitrogen.
According to some embodiments of the invention, the obtained dry matter is redissolved by methanol, then is subjected to ultrasonic treatment, vortex mixing is carried out, and supernatant is centrifugally taken for separation.
According to some embodiments of the invention, wherein the centrifuging comprises centrifuging at 8000rpm/min to 12000rpm/min for 10-5min.
According to some embodiments of the invention, the rotational speed of the centrifugation is 12000rpm/min.
According to some embodiments of the invention, the centrifugation time is 5min.
According to some embodiments of the invention, wherein the body fluid is from an individual on day 8 to day 10 after administration.
According to some embodiments of the invention, wherein, when the body fluid is blood, the body fluid is a mixture of body fluids from individuals at 10min, 30min, 1h, 3h, 6h, 9h, 12h, 16h, 25h, and 48h on day 8 after administration; when the body fluid is urine, the body fluid is a mixture of body fluids from individuals at the following time period on day 8 after administration: 0-4h,4-10h,10-24h,24-32h and 32-48h.
On the other hand, the invention also provides a structure identification method of the related metabolite of the even flower antipyretic drug, wherein the method comprises the steps of separating the related metabolite in the body fluid of an individual to which the even flower antipyretic drug is administered by using the separation method, and then carrying out structure analysis by using a high-resolution mass spectrum.
According to some embodiments of the invention, the method comprises structural analysis using mass spectrometry conditions as follows: an ESI ion source; a positive and negative ion detection mode; full MS Full scan resolution: 70000, scanning mass range: 100-1200Da; full ms/ddMS2 collision energy: 30eV; full MS resolution: 35000; ddMS2 resolution: 17500.
according to some embodiments of the invention, wherein the mass spectrometry conditions further comprise: spray Voltage (Spray Voltage): 3.8kV; capillary voltage (Capillary Voltage): 40V; capillary temperature (Ion Transfer Tube Temperature): 300 ℃; vaporization temperature (Vaporizer Temperature): 350 ℃; sheath air flow rate (Sheath Cas Flow Rate): 35arb; auxiliary gas flow rate (Auxiliary Gas Flow Rate): 10arb; sweep tail gas flow rate (Sweep Gas Flow Rate): 5arb; RF Lens (%): 50; AGC Target:3.0e6.
According to some embodiments of the invention, wherein the sheath gas is N 2 。
According to some embodiments of the invention, wherein the assist gas is N 2 。
According to some embodiments of the invention, the sweep tail gas is N 2 。
According to some embodiments of the invention, wherein the mass spectrometry conditions further comprise: MS2 employs Data Dependent Scan to set Top 10 ions for collision induced dissociation, isolation Window (m/z): 2.0; (N) CE/stepped (N) CE:35; ddMS scan resolution: 17500; dynamic exclusion (Dynamic Exclusion): 10s.
According to some embodiments of the invention, wherein the high resolution mass spectrum is a Thermo Fisher Q Exactive mass spectrometer (liquid mass spectrometer).
According to some embodiments of the invention, the method comprises obtaining in vivo metabolite high resolution mass spectrum data (including retention time, HRMS and MS/MS data sets) of the even flower antipyretic capsule using the mass spectrum conditions described above, and identifying the structure of the even flower antipyretic drug related metabolite using the following method:
1) Deriving a structure for the compound with the reference substance according to the cleavage rule of the reference substance;
2) Performing structural characterization according to high-resolution mass spectrum data on the compound without the reference substance;
3) For compounds whose structure was not deduced by both methods, analysis was aided by Compound Discoverer software.
According to some embodiments of the invention, the deriving the structure with reference to the cleavage law of the reference substance comprises deriving the cleavage law of the reference substance from the collected high-resolution HRMS and MS/MS data, and identifying the structure of the reference substance by comparing the cleavage law with the cleavage law of the reference substance.
According to some embodiments of the invention, wherein the structural characterization from high resolution mass spectrometry data for the compound without the control comprises: firstly, according to the obtained accurate HRMS data, the molecular formula of the compound is presumed; then, the cleavage rules are deduced according to MS/MS characteristic fragment ion information, and compared with mass spectrum information (such as retention time, molecular formula, mass spectrum cleavage rules and the like) of the compound with the determined structure, and literature reports are used for deducing the structure of the compound.
According to some embodiments of the invention, wherein for compounds for which the structure is not deduced by both methods, the analysis assisted by Compound Discoverer software comprises: high-resolution HRMS/MS mass spectrum data of body fluid samples of the Lianhua qingwen capsule are imported into Compound Discoverer software, search parameters are set, and the Lianhua qingwen capsule is linked to a local natural product database built by Chemspider, pubmed, m/z Cloud and other Thermo companies to search, and matching degree scoring is adopted; and finally, synthesizing matching scoring results of all databases, and presuming the structure of the compound.
In conclusion, the invention provides a method for separating and identifying the metabolic products related to the even flower antipyretic drugs. The method of the invention has the following advantages:
1) The method can quickly and effectively separate the related metabolites of the even flower antipyretic drugs in the body fluid;
2) According to the invention, a high-resolution mass spectrometer is adopted to comprehensively collect accurate mass spectrum data of related metabolites of the even flower antipyretic drugs, a reasonable molecular formula is calculated, and the structural identification is completed.
Drawings
FIG. 1 is a graph of the high-resolution extracted particle stream of the components related to Lianhua qingwen capsule (A) and the negative ion and the positive ion in a human plasma sample of example 2;
fig. 2 is a high-resolution extract particle flow chart (a) of the related components of the Lianhua qingwen capsule and a high-resolution extract ion flow chart (B) of the positive ions in the human urine sample of example 2.
Detailed Description
The following detailed description of the invention and the advantages achieved by the embodiments are intended to help the reader to better understand the nature and features of the invention, and are not intended to limit the scope of the invention.
Example 1
The embodiment provides a method for separating related metabolites of a coptis chinensis antipyretic drug, which comprises the following steps:
1. clinical sample collection
A single-site, randomized, open, multiple-dosing trial design approach was used to enroll a group of 14 healthy subjects or appendiceectomies. Each subject has no heart, liver and kidney diseases proved by physical examination, laboratory examination, electrocardiogram and the like; there was no history of allergy and no even flower antipyretic capsules or other drugs or foods that could affect drug absorption, distribution, metabolism, excretion were taken within one month prior to the test. The study protocol was approved by the ethical committee of the Hebei Kagaku Hospital, and all subjects signed written informed consent prior to entry into the study. The test was performed in a continuous administration manner of 1-8 days (except for 2 days) (administration dose is 4.2g (Lianhua qingwen capsule 12 granules)), sampling (blood and urine) 1 st day sampling (blood and urine) to 48h after administration, pre-administration blood sampling 3-7 days, sampling 8 th day sampling (blood and urine); the test period was 11 days. Breakfast was taken 1h before the intake and after the meal was completed within 30min, the test drug was taken on time 1h after the start of the meal. Taken with 240mL of warm water. The collected blood plasma and urine samples are stored in a refrigerator at about-80 ℃ to be tested.
2. Biological sample preparation
Plasma samples of 6 subjects (subject numbers 1, 3, 6, 8, 9, 12) were mixed for 10min, 30min, 1h, 3h, 6h, 9h, 12h, 16h, 25h, and 48h on the eighth day, 50 μl plasma was taken per time point for each subject, giving 3mL mixed plasma samples. Diluting with ultrapure water three times, respectively passingAn HLB 3cc (60 mg) Extraction Cartridges (Batch No. 164A 39127A) column was enriched and purified, and methanol eluate was collected and dried with nitrogen; the residue was reconstituted with 100. Mu.L of 70% methanol, sonicated for 10s, vortexed, and centrifuged at 12000rpm/min for 5min, and the supernatant was analyzed. Blank plasma samples were prepared in the same way before dosing.
Taking urine samples (comprising 0-4h,4-10h,10-24h,24-32h,32-48h, etc.) of the eighth day after 6 subjects (subject numbers 1, 3, 6, 8, 9, 12) are dosed, combining after freeze thawing, and taking 100 microliter urine samples for each subject at each time point to obtain 3mL mixed urine samples; after enrichment and purification by Oasis HLB SPE (60 mg/3 cc) column, methanol eluent is collected, after drying by nitrogen at 37 ℃, residues are respectively redissolved by 100 mu L of 70% methanol, dissolved by ultrasonic for 10s, vortex mixed evenly, centrifuged at 12000rpm/min for 5min, and the supernatant is taken for analysis. Blank urine samples were prepared in the same manner.
UPLC-HRMS analysis conditions
Instrument and equipment
Thermo Fisher Q Exactive liquid chromatography mass spectrometer, product of Thermo company, usa; xcalibur 3.0.63 (Thermo Fisher) chemical workstation data processing system.
Chromatographic conditions
Chromatographic column: ACQUITY UPLC CSH C18 (2.1×50mm,1.7 μm);
mobile phase composition: a, 0.1% formic acid aqueous solution; acetonitrile
Mobile phase gradient: 0-3min (2% -2% B); 3-4min (2% -5% B); 4-6min (5% -5% B); 6-9min (5% -10% B); 9-14min (10% -15% B); 14-18min (15% -20% B); 18-25min (20% -30% B); 25-28min (30% -95%), 28-32min (95% -95%), 32.01min (95% -5% B); 32.01-37min (5% -5% B).
Flow rate: 0.3mL/min; sample injection amount: 3 μL; column temperature: 35 ℃.
Example 2
The embodiment provides a structure identification method of a related metabolite of a coptis chinensis antipyretic drug, which comprises the following steps:
in vivo metabolites of the Lianhua qingwen capsule were isolated following the procedure of example 1 and then structurally resolved with a Thermo Fisher Q Exactive liquid chromatography-mass spectrometer, wherein mass spectrometry conditions included:
an ESI ion source, positive and negative ion detection mode; full MS Full scan resolution: 70000, scanning mass range: 100-1200Da; full ms/ddMS2 collision energy: 30eV; full MS resolution: 35000; ddMS2 resolution: 17500; spray voltage: 3.8kV; capillary voltage: 40V; capillary temperature: 300 ℃; gasification temperature: 350 ℃; sheath gas (N) 2 ) Flow rate: 35arb; auxiliary gas (N) 2 ) Flow rate: 10arb; sweep tail gas (N) 2 ) Flow rate: 5arb; RF Lens:50; AGC Target:3.0e6.MS2 employs Data Dependent Scan to set Top 10 ions for collision induced dissociation, isolation Window (m/z): 2.0; (N) CE/stepped (N) CE:35; ddMS scan resolution: 17500; dynamic exclusion (Dynamic Exclusion): 10s.
And carrying out structural identification according to the following steps:
after in-vivo metabolite high-resolution mass spectrum data (comprising retention time, HRMS and MS/MS data sets) of the Lianhua qingwen capsule are comprehensively collected according to the conditions, analyzing a Lianhua qingwen capsule reference substance by using the same conditions, and obtaining accurate retention time, HRMS and MS/MS mass spectrum data information and mass spectrum cracking rules of the Lianhua qingwen capsule reference substance. Then, compound structure identification is carried out, and the specific structure identification process is mainly divided into three types:
1) The structure is deduced according to the cracking rule of the reference substance for the compound with the reference substance. Deducing a compound cracking rule according to the collected high-resolution HRMS and MS/MS data, and comparing the compound cracking rule with a cracking rule of a reference substance to identify a compound structure.
2) And (3) carrying out structural characterization according to high-resolution mass spectrum data on the compound without the reference substance. Firstly, according to the obtained accurate HRMS data, the molecular formula of the compound is presumed; then, the cleavage rules are deduced according to MS/MS characteristic fragment ion information, and compared with mass spectrum information of the compound with the determined structure, such as retention time, molecular formula, mass spectrum cleavage rules and the like, and literature reports, the structure of the compound is deduced.
3) For compounds whose structure was not deduced by both methods, analysis was aided by Compound Discoverer software. High-resolution HRMS/MS mass spectrum data of body fluid samples of the Lianhua qingwen capsule are imported into Compound Discoverer software, search parameters are set, and the Lianhua qingwen capsule is linked to a local natural product database built by Chemspider, pubmed, m/z Cloud and other Thermo companies to search, and matching degree scoring is adopted; and finally, synthesizing matching scoring results of all databases, and presuming the structure of the compound. The traditional Chinese medicine compound (Chinese traditional medicine; TCM) has complex and various components, usually contains hundreds of original components of medicines, and each component can be changed along with environmental factors and processing conditions, and can generate more complex and various compounds through various biological metabolism transformation paths after entering the human body or animal body. There are many difficulties in developing studies, particularly in developing metabolic processes in vivo. Screening 126 compounds in plasma and urine samples; of these, 101 were detected in plasma and 111 were detected in urine. The data relating to specific compounds are shown in Table 1 (Table 1 lists the total number of compounds detected in the three matrices, lianhua qingwen capsule, plasma and urine). The high resolution extraction particle flow patterns of the related components of the Lianhua qingwen capsule in human plasma and urine samples are shown in fig. 1 and fig. 2.
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
Claims (9)
1. The method comprises the steps of enriching and purifying body fluid by using an Oasis HLB column, separating the relevant metabolites in the body fluid of an individual to which the even flower antipyretic drug is administered by using the following chromatographic conditions, and carrying out structural analysis by using high-resolution mass spectrometry, wherein the body fluid is blood and/or urine:
chromatographic column: a C18 chromatographic column;
mobile phase: a:0.1% formic acid aqueous solution, B: acetonitrile;
flow rate: 0.2-0.3mL/min;
column temperature: 30-40 ℃;
the method comprises eluting with a mobile phase gradient as follows:
0-3 min：2%-2% B、3- 4 min：2%-5% B、4-6 min：5%-5%B、6-9 min：5%-10%B、9-14 min：10%-15% B、14-18 min：15%-20% B、18-25 min：20%-30% B、25-28min：30%-95% B、28-32min：95%-95% B、32 min：95%-5% B、32-37 min：5%-5%B；
the mass spectrometry conditions included: an ESI ion source; a positive and negative ion detection mode; full MS Full scan resolution: 70000, scanning mass range: 100-1200Da; full ms/ddMS2 collision energy: 30eV; full MS resolution: 35000; ddMS2 resolution: 17500; ESI ion source, spray voltage: 3.8 A kV; capillary voltage: 40V, V; capillary temperature: 300 o C, performing operation; gasification temperature: 350 o C, performing operation; sheath air flow rate: 35 an arb; auxiliary gas flow rate: 10 an arb; sweep tail gas velocity: 5arb; RF Lens:50; AGC Target:3.0e6.
2. The method of claim 1, wherein the method further comprises eluting with a mobile phase gradient of:
0-3min:2% -2% of B and 3-4min:2% -5% of B and 4-6min:5% -5% of B and 6-9min:5% -10% of B and 9-14min:10% -15% of B and 14-18min:15% -20% of B and 18-25min:20% -30% of B and 25-28min:30% -95%, 28-32min:95% -95%, 32.01min:95% -5% of B and 32.01-37min:5% -5% of B; wherein the B concentration is increased at a constant rate during each period of time in which the B concentration is increased.
3. The method of claim 1, wherein the chromatography column is a ACQUITY UPLC CSH C18 chromatography column.
4. The method of claim 1, wherein the chromatographic conditions further comprise a sample loading of 3 μl.
5. The method of any one of claims 1-4, wherein the coptis chinensis antipyretic drug is a coptis chinensis antipyretic capsule or a coptis chinensis antipyretic granule.
6. The method of any one of claims 1-4, wherein the individual is a human.
7. The method according to any one of claims 1 to 4, wherein the method comprises subjecting the body fluid to column chromatography, eluting with methanol, drying, re-dissolving the obtained dried product with methanol, and centrifuging to obtain supernatant for separation.
8. The method of any one of claims 1-4, wherein the bodily fluid is from an individual on days 8-10 after administration.
9. The method of claim 8, wherein when the body fluid is blood, the body fluid is a mixture of body fluids from individuals at 10min, 30min, 1h, 3h, 6h, 9h, 12h, 16h, 25h, and 48h on day 8 post-administration; when the body fluid is urine, the body fluid is a mixture of body fluids from individuals at the following time period on day 8 after administration: 0-4h,4-10h,10-24h,24-32h and 32-48h.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010742940.3A CN114062566B (en) | 2020-07-29 | 2020-07-29 | Method for separating and identifying structure of related metabolites of even flower antipyretic drugs |
| PCT/CN2021/080377 WO2022021886A1 (en) | 2020-07-29 | 2021-03-12 | Method for separation and structural identification of relevant metabolites of lianhua qingwen drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010742940.3A CN114062566B (en) | 2020-07-29 | 2020-07-29 | Method for separating and identifying structure of related metabolites of even flower antipyretic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114062566A CN114062566A (en) | 2022-02-18 |
| CN114062566B true CN114062566B (en) | 2023-11-10 |
Family
ID=80037109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010742940.3A Active CN114062566B (en) | 2020-07-29 | 2020-07-29 | Method for separating and identifying structure of related metabolites of even flower antipyretic drugs |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114062566B (en) |
| WO (1) | WO2022021886A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117686622B (en) * | 2024-02-02 | 2024-05-14 | 江西中医药大学 | Analysis method of multiple components in eight-ingredient zichongkusan |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105974029A (en) * | 2016-07-11 | 2016-09-28 | 山东省分析测试中心 | Method for simultaneously determining six iridoid glycoside type components in Lianhua Qingwen capsules |
| CN109270187A (en) * | 2018-11-02 | 2019-01-25 | 江苏省中医院 | A kind of Chinese materia medica preparation quality evaluating method based on metabolism group Yu full ingredient semi-quantitative analysis |
-
2020
- 2020-07-29 CN CN202010742940.3A patent/CN114062566B/en active Active
-
2021
- 2021-03-12 WO PCT/CN2021/080377 patent/WO2022021886A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105974029A (en) * | 2016-07-11 | 2016-09-28 | 山东省分析测试中心 | Method for simultaneously determining six iridoid glycoside type components in Lianhua Qingwen capsules |
| CN109270187A (en) * | 2018-11-02 | 2019-01-25 | 江苏省中医院 | A kind of Chinese materia medica preparation quality evaluating method based on metabolism group Yu full ingredient semi-quantitative analysis |
Non-Patent Citations (7)
| Title |
|---|
| Identification of absorbed components and their metabolites in rat plasma after oral administration of Shufeng Jiedu capsule using ultra‐performance liquid chromatography/quadrupol e time‐of‐flight mass spectrometry;Xinyi Liu 等;Rapid Commun Mass Spectrom;第33卷;1494-1501 * |
| Pharmacokinet ic Study of Bioactive Flavonoids in the Traditional Japanese Medicine Keigairengyoto Exerting Antibacterial Effects against Staphylococcus aureus;Takashi Matsumoto;Int. J. Mol. Sci.;第19卷(第328期);1-16 * |
| UHPLC-QTOF-MS/MS技术的铁筷子中3个香豆素在大鼠体内代谢研究;张晶等;中国中药杂志;第43卷(第21期);4330-4338 * |
| UPLC-Q-TOF/MS法鉴定兽药磺胺二甲嘧 啶在小鼠血液和尿液中的代谢产物;孙汉文等;河北大学学报(自然科学版);第35卷(第02期);131-137,224 * |
| UPLC-Q-TOF-MS法分析连花清瘟胶囊的入血成分;于华等;天津中医药;第33卷(第12期);756-756 * |
| 基于UPLC-Q-TOF-MS技术的连花清瘟胶囊药效物质基础研究;王海荣等;中国博士学位论文全文数据库 医药卫生科技辑(第08期);E057-118 * |
| 新绿原酸的大鼠体内代谢产物的 UPLC-Q-TOF MS鉴定;李洁等;中国现代中药;第22卷(第07期);1048-1055,1071 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022021886A1 (en) | 2022-02-03 |
| CN114062566A (en) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105467059B (en) | A kind of quality determining method for the Chinese medicine composition for treating blood urine | |
| CN109030663B (en) | Method for detecting chemical components in compound liquorice tablets by UHPLC (ultra high performance liquid chromatography) method | |
| CN107607649B (en) | Method for detecting periploca forrestii schltr | |
| WO2021168855A1 (en) | Content determination method for material and application thereof | |
| CN113063885B (en) | Composition for preparing Baoyuan decoction, baoyuan decoction product and fingerprint spectrum measuring and quality detecting method thereof | |
| CN107315061B (en) | A kind of detection method of alizarin root of Dahurian angelica Chinese materia medica preparation that treating uterus bleeding | |
| CN109100442A (en) | The detection method of internal directly action component in Heiguteng exract medicinal material | |
| CN114062566B (en) | Method for separating and identifying structure of related metabolites of even flower antipyretic drugs | |
| Zhou et al. | Integrated plasma pharmacochemistry and network pharmacology to explore the mechanism of Gerberae Piloselloidis Herba in treatment of allergic asthma | |
| Jin et al. | Comprehensive characterization of the chemical composition of Lurong dabu decoction and its absorbed prototypes and metabolites in rat plasma using UHPLC–Q Exactive Orbitrap–HRMS | |
| CN107543889A (en) | A kind of rhodiola kirilowii Regel capsule fingerprint pattern and its construction method | |
| CN101884746B (en) | Method for detecting capsules for treating cough with asthma | |
| Yang et al. | Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach | |
| CN110988198A (en) | Content determination method of bi-tong ning capsules | |
| CN113671091B (en) | Method for detecting blood-entering chemical components of four ministerial cough-relieving particles | |
| Zhao et al. | Systems pharmacology approach and experiment evaluation reveal multidimensional treatment strategy of LiangXueJieDu formula for psoriasis | |
| CN106501389A (en) | A kind of Essence of Intrinsic Change of Chinese Medicines Through Preparation research method | |
| CN103405664B (en) | Daochi powder formula granule as well as preparation method, use and detection method thereof | |
| Xiong et al. | Identification of quality markers of Xiaojin Pills using a combination of high-performance liquid chromatographtandem mass spectrometry and multivariate analysis | |
| CN107389818B (en) | A kind of drug for treating Parkinson and preparation method thereof and detection method and purposes | |
| CN101936974B (en) | Method for identifying Chinese patent drugs by using mixed contrast | |
| CN112190684A (en) | A Chinese medicinal composition for treating intractable cough and asthma, and its preparation method and quality control method | |
| Yao et al. | Simultaneous quantitation and comparison of eight components in Jiao‐ai decoction and Si‐wu decoction by ultra high performance liquid chromatography with triple quadrupole tandem mass spectrometry | |
| CN106018577B (en) | Three yellow party formulation ingredients detection methods and fingerprint map construction method | |
| CN104007187A (en) | Detection method for safflower-qili capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |